Referral MD

FEBRUARY 28, 2025

While medical science advances, too many clinics still rely on cumbersome paperwork. For too long, the administrative side of healthcare has lagged behind its clinical advancements. Once prescribed the medication, you can include questions about weight loss and side effects to assess progress and make necessary adjustments.

Healthcare 52

Healthcare Healthcare Patients Electronics 52

European Pharmaceutical Review

MAY 23, 2024

About the interviewee Imran Khan, MD, PhD is Vice President Medical Affairs, Hematology at Johnson & Johnson Innovative Medicine. Most recently, Imran has served as Medical Science Liaison (MSL) Head, Oncology U.S. Medical Affairs. CAR T-cell Therapy and its side effects [Internet]. Cancer.gov.

Food and Drug Administration 110

Food and Drug Administration Food Medical Medicine 110

Medgadget

FEBRUARY 17, 2023

Thanks to kind support from Biomed Israel , the leading international Life Science and HealthTech conference in Israel (see more below), we met with Ronan Castro, the CEO of Human Xtensions at the company’s offices in Netanya, Israel. More info can be found at the Biomed Israel website.

Physicians 80

Physicians Engineering Leads Side effects 80

PM360

APRIL 22, 2024

Medical science Liaisons know that change is coming; How are they cashing in? Medical science liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering.

Medical 52

Medical Education Medical science Customer Relationship Management 52

Celeritas

OCTOBER 23, 2022

This means that during the Q&A session, you may face a myriad of intricate medical, functional, or operational questions. A Medical Science Liaison’s job is to build relationships, so distinguishing yourself in these ways is paramount. For a Medical Science Liaison, having medical knowledge is a given necessity.

Medical science 40

Medical science Medical Specialization Doctors 40

European Pharmaceutical Review

AUGUST 15, 2024

1 The cancer is a slow-growing but potentially life-threatening B-cell malignancy, in which increased activation of B-cell receptor signalling pathways leads to overgrowth of lymphocytes in bone marrow and other disease compartments. About the author Dr Mehrdad Mobasher, MPH, is the Chief Medical Officer for Hematology at BeiGene.

Safety 52

Safety Patients Medical Medicine 52